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Prevalence of human papillomavirus (HPV) and HPV-16 
genotyping by real-time PCR in patients with several 
cervical pathologies
ABSTRACT
Purpose: this study was planned to evaluate the prevalence of HPV (excepting type 16) and HPV 
16 by real-time PCR in colposcopy patients and to interprete the results with age, age of first sexual 
intercourse (FSI), parity and Pap smear results. Methods: one hundred and two colposcopy patients 
(50 and 52 of the patients were classified as colposcopy positive and negative, respectively) applying 
to Gynecology clinic were included. HPV (excepting type 16) and HPV 16 were detected by real-
time PCR using the L1 region. Real-time nested amplifications of MY09/11 products were done by 
GP5+/GP6+ primers and Cyanine-5 labeled HPV and HPV 16 DNA specific probe after HPV DNA 
extraction by phenol chloroform isoamylalcohol. Results: HPV (excepting type 16) and HPV 16 
were positive in 12% and 18% of the colposcopy positive patients respectively. HPV (excepting type 
16) and HPV 16 were positive in 5.7% and 3.8% of the colposcopy negative patients, respectively. 
Conclusion: there was a statistically significant difference between colposcopy positive and col-
poscopy negative patients comparing HPV 16 with total HPV positivity (p = 0.021 for type 16 and 
p = 0.010 for total HPV) but there was not a statistically significant difference between colposcopy 
positive and colposcopy negative patients when we compared HPV (excepting type 16) positivity 
(p = 0.314). In conclusion, HPV detection and typing may be helpful for cervical cancer screening 
and prevention.
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INTRODUCTION
Cervical cancer is globally the second most com-
mon cancer in women with approximately 493,000 
new cases annually.1 Also cervical cancer is an im-
portant public health problem in developing coun-
tries. There is a statistically significant relationship 
between cervical cancer and the number of sexual 
partners of a woman. These data direct us to sexu-
ally transmitted agents, especially viruses.2,3 As a 
result of the epidemiological studies on cervical 
cancer, there is no doubt about the importance 
of human papillomavirus (HPV), especially type 
16 and 18, as an aetiological agent.2-5 As a conse-
quence, the detection and treatment of HPV infec-
tion can be an important stage in diagnosis and 
treatment of cervical cancer. The Pap smear test, 
as the most widely used cancer screening test in 
the world, is cost effective and organised screen-
ing provided a decline in cervical cancer mortality. 
However, in developing countries, where screen-
ing programmes are uncommon, cervical cancer 
still remains as one of the most important causes 
of death among women. HPV can only be reliably 
detected by DNA based tests since morphological 
changes on cytology such as koilocytosis are not 
specific for oncogenic HPVs. These observations 
underscore the need to develop more effective 
diagnostic methods.6,7 PCR based methods am-
plifying nucleic acids of HPV are commonly used 
because of the limited sensitivity of Pap smear test 
leading to sample preparation and interpretation 
problems, insufficient serological tests and im-
possibility of in vitro cultures. Detection of HPV 
DNA, especially in latent infections, can be help-
ful in detecting cancer and precursor lesions.8 This 
study was designed to evaluate the effect of HPV, 
especially type 16 in colposcopy patients, both with 
and without cervical pathologies and to associate it 
with the clinical findings in our hospital.
MATERIAL AND METHODS
Patients: from December 2003 to October 2004, 
patients directed to colposcopy were includ-
ed in the study. After acetic acid application, 
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observation of cervical acetowhite epithelium, punctuation, 
atypical vascularisation or mosaic pattern in colposcopic 
examination were classified as colposcopy positive patients, 
and patients with normal colposcopic findings were clas-
sified as colposcopy negative. All colposcopy patients were 
screened by Pap smear test and replied a questionnaire in-
cluding questions, such as age, age of FSI, and parity. 
Samples: cervical smear samples were collected in tubes 
containing 3-5 mL sterile phosphate buffered saline (PBS) in 
Gynecology Clinic of Gazi University Medical Faculty from 
colposcopy patients before application of acetic acid. After 
transporting to molecular diagnosis laboratory, all samples 
were vortexed and aliquoted in 1.5 mL eppendorf tubes and 
frozen at -86º C until DNA extraction. 
DNA extraction: the cervical samples were digested in a 
buffer containing 20 mg/mL proteinase K (20 mM (NH
4
)
2
SO
4
, 
75 mM Tris HCl [pH 8,8] 0,1% Tween 20) at 55° C for 3 hours; 
followed by 10 minutes at 95°C. DNA isolation was performed 
by phenol-chloroform extraction and ethanol precipitation. 
DNA was then suspended in sterile distilled water and stored at 
-86° C until amplification.
DNA amplification: nested real-time PCR method was 
used for the analysis of HPV DNA and HPV 16 positivity. 
MY09/11 primer set (5’-CGTCCMARRGGAWACTGATC-3’), 
(5’-CMCAGGGWCATAAYAATGG-3’, Tib Molbiol, Germany) 
was used for PCR amplifications following the extraction of the 
DNA. Real-time nested amplifications of MY09/11 products 
were done by GP5+/GP6+ primers and Cyanine-5 labeled HPV 
16 DNA specific probe [Primer F 5’ TTTGTTACTGTGGTA-
GATACTAC 3’, Primer R 5’ GAAAAATAAACTGTAAATCAT-
ATTC 3’, Cy5.0 signal probe 5’ Cy5-GTTTCTGAAGTAGATAT-
GGCAGCACA-biotin 3’ (Tib Molbiol, Germany)]. Real-time 
PCR product analysis was done by melting curve analysis on 
LightCycler Software version 3.5.3 (LC 2.0 Roche Diagnostics, 
Germany). Melting peaks of 78-82° C showed the detection of 
HPV DNA in the sample. Probe melting peaks of positive sam-
ples have been analyzed in the same run and HPV 16 positive 
samples yielded peaks around 68° C. 
Ethical review of the proposal and the consent
The research proposal was approved by the ethical review 
board of the Faculty of Medicine, Gazi University. Informed 
consent was obtained from all women prior to the sample 
collection. 
RESULTS 
A total of 50 colposcopy positive women (18-63 years 
old; mean age ± SD: 39 ± 7) and 52 colposcopy negative 
women (17-65 years old; mean age ± SD: 40 ± 9) were in-
cluded in the study. There was a statistically significant 
difference between colposcopy positive and colposcopy nega-
tive patients when we compared HPV 16 and total HPV posi-
tivity by Pearson chi-square test (p = 0.021 for type 16 and 
p = 0.010 for total HPV) but there was not a statistically sig-
nificant difference between colposcopy positive and colposco-
py negative patients when we compared HPV (excepting type 
16) positivity by Fisher’s exact test (p = 0.314) (Table 1).
According to age of women included in the study there 
was not a statistically significant difference between patients 
age ≤ 34 and ≥ 35 when we compared HPV 16 and HPV 
(excepting type 16) positivity by Fisher’s exact test (p = 0.154)
for type 16 and p = 0.240 for HPV (excepting type 16) but 
there was a statistically significant difference between patients 
age ≤ 34 and ≥ 35 when we compared total HPV positivity by 
Pearson chi-square test (p = 0.036) (Table 2).
There was no statistically significant difference between 
FSI in patients ≤ 19-year old and FSI in patients ≥ 20-year old 
when we compared HPV 16, HPV (excepting type 16) and 
total HPV positivity by Fisher’s exact test (p = 0.505 for type 
16, p = 0.159 for HPV (excepting type 16) and p = 0.650 for 
total HPV) (Table 2).
Parity seems statistically significant between 0-2 parity 
patients and ≥ 3 parity patients when we compared HPV 16, 
HPV (excepting type 16) and total HPV positivity by Fish-
er’s exact test (p = 0.037 for type 16 and p < 0.001 for HPV 
(excepting type 16) and p < 0.001 for total HPV) (Table 2). 
Table 1. Distribution of HPV DNA PCR results according to patient groups
 Colposcopy Colposcopy  X2
 positive (n = 50) negative (n = 52) 
HPV  16 (+) 
n (%) 9 (18%) 2 (3.8%) p = 0.021
HPV (+)   
n (%) 6 (12%) 3 (5.7%) p = 0.314a
Total HPV (+) 
n (%) 15 (30%) 5 (9.5%) p = 0.010
a:Fisher’s exact was used.
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According to examination of Pap smear results, there 
was not a statistically significant difference between the pa-
tients with normal Pap smear and pathological Pap smear 
when we compared HPV 16 and HPV (excepting type 16) 
positivity by Fisher’s exact test (p = 0.169 for type 16 and 
p = 0.254 for HPV (excepting type 16) but the p value was 
0.050 by Pearson chi-square test which is a borderline value 
when we compared total HPV positivity (Table 2).
DISCUSSION
Because HPV, especially type 16, is reported as an important 
risk factor for development of cervical dysplasia and cancer, 
and 99.7% of the cervical cancers can be proved related to 
HPV, one of the main goals of preventing cervical cancer is 
screening for HPV.9 
Tuncer et al.10 detected in their study 12.5%, 19.4%, 
46.3% and 83.3% of HPV type 16 positivity in CIN I, CIN 
II, CIN III and invasive carcinoma specimens, respectively, 
by PCR in Turkish patients. Also Onan et al.11 from Turkey 
found 4.2%, 14.8%, 45% HPV positivity in CIN I, CIN II, 
and CIN III specimens, respectively, and HPV positivity in 
patients with CIN III was significantly higher than in pa-
tients with CIN I and CIN II.
In 102 colposcopy patients (both colposcopy positive 
and negative), a 19.6% of positivity in favour of total HPV 
was detected in our study, 9.5% positivity and 30.0% positiv-
ity in colposcopy negative and positive groups, respectively. 
This result indicates that there is a statistically significant 
difference between two groups (p = 0.010).
In joint assessment of HPV (excepting type 16) and 
HPV 16 we found a 55% of positivity in patients young-
er than 34 and a 45% of positivity in patients older than 
35. Our results correlate with the studies indicating a de-
crease in HPV infection as the age increases,12-15 although 
Ko et al.16 in their study found that women between ages 
30-69 had lower HPV positivity rate (ranging from 14-
34%) compared to women with younger than 30 and older 
than 70 (ranging from 47-52%). 
Considering total HPV, we found 70% positive cases in 
the group who experienced their FSI at the age of 19 or be-
fore, and 30% positive cases in the group who experienced 
Table 2. Distribution of HPV positivity according to variables
Number of patients(n)  HPV 16 HPV Total HPV
    (n = 11) (n = 9) (n = 20)
   n         % N         % n         %
Age
Age ≤ 34 (n = 75)   6         54.5 5         55.5 11         55
Age ≥ 35 (n = 27)   5         45.5 4         44.5 9         45
X2   p = 0.154a p = 0.240a p = 0.036
Age of FSI
Age ≤ 19 (n = 67)   6         54.5 8         88.2 14         70
Age ≥ 20 (n = 35)   5         45.5 1         11.8 6         30
X2   p = 0.505a p = 0.159a p = 0.650a
Parity
0-2       (n = 82)   6         54.5 2         22.2 8         40
≥ 3       (n = 20)   5         45.5 7         77.8 12         60
X2   p = 0.037a p < 0.001a p < 0.001a
Pap smear
Normal (n = 74)   6         54.5 5         55.5 11         55
Pathological (n = 28)  5         45.5 4         44.5 9         45
X2   p = 0.169a p = 0.254a p = 0.050
FSI: first sexual intercourse.
a:Fisher’s exact was used.
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their FSI at the age of 20 or after. Although there is not a 
statistically significant difference between the two groups 
and HPV results, our findings confirmed the findings of 
previous studies12,17,18 that HPV infection is more common 
among women who experienced their FSI in the early ages. 
Consequently, Flores et al.19 indicate in their study that older 
age at FSI is significantly associated with a decreased risk of 
high grade CIN or cancer in HPV(+) women.
There are contradictory results in the studies evaluating 
HPV-cervical cancer and parity relationship, some of which 
suggest that there is no association with parity and HPV-
cervical cancer.20,21 Considering all HPV types, 40% positive 
cases in the group who gave two or less births and 60% posi-
tive cases in the group who gave three or more births were 
found in our study and HPV seems statistically significant 
between 0-2 parity patients and ≥ 3 parity patients when we 
compared HPV 16, HPV (excepting type 16) and total HPV 
positivity. Shields et al.22 and Castellsague et al.23 suggest that 
HPV exposed women with high parity are at increased risk 
for cervical cancer. Our study suggests that parity seems a 
risk factor for HPV and consequently for cervical cancer. On 
the contrary, Sellors et al.17 in Canada detected a positivity 
of 17.1% in women who never gave birth, 12.7% in women 
who gave one birth, 8.7% in women who gave two births 
and 6.5% in women who gave three or more births. 
We first performed colposcopy and cytology and than 
detected HPV DNA by real-time PCR. It is suggested that, as 
compared to Pap testing, HPV testing has greater sensitivity 
for the detection of CIN,24 and the addition of a HPV test 
to a Pap test to screen women in their mid 30’s for cervical 
cancer reduces the incidence of grade 2 or 3 CIN or can-
cer.25 Cuzick26 emphasizes in a review that detection of HPV 
DNA by molecular tests is more sensitive but less specific 
and therefore the use of these methods together must be the 
gold standard in cervical screening programs. 
Grce et al.27 detected HPV DNA in colposcopy positive 
patients in Zagreb. The results were 64.4% positive. As they 
detected the smears cytologically, they came to the conclusion 
that as the grade of SIL increased there was an increase in the 
prevalance of high risk HPVs (HPV DNA type 16 prevalance 
was 8.5% and 17.1% in LSIL and HSIL cases, respectively). 
The results were found to be statistically significant. Fife et 
al.28 found 35% HPV 16 positivity in women with pathologi-
cal Pap smear results in their study by PCR. All ASCUS, LSIL, 
HSIL, CIN I, CIN II, CIN III cases in our study were consid-
ered as pathological Pap smear results. We found 45.5% HPV 
16 positivity in women with pathological Pap smear results. 
While 45% positivity (total HPV) was found in the group 
with pathological Pap smear results, the ratio of HPV positiv-
ity (total HPV) was 55% in the group with normal Pap smear 
results. Our results are not correlated with literature results. 
The reason for this declination may be due to sample prepara-
tion or smear results interpretation. 
HPV DNA, especially type 16, followed by type 18, 45, 
31 and 33 is diagnosed in more than 99% of cervical cancer 
biopsies. Although the ratios change according to the diag-
nosis method, HPV type 16 is detected in 33-50% of cervi-
cal cancer tissues and this is the main reason to focus on 
type 16.29 Antonishyn et al.30 found in their study that the 
most commonly identified genotype in patients with cervi-
cal intraepithelial neoplasia grade 2 or worse was HPV-16 
(46.7%), followed by HPV-31 (14.7%) and HPV-18 (3.9%) 
by real-time polymerase chain reaction. They found that 
HPV-31 is contributing significantly to the proportion of 
women with cervical intraepithelial neoplasia in their study 
population and shows a higher prevalence than HPV-18 in 
high-grade lesions. 
We studied smear samples and found a 19.6% positiv-
ity in all colposcopy patients. This result shows the high 
sensitivity of real-time PCR. Real-time PCR, the most ad-
vanced and sensitive of the molecular methods, was used 
in our study. Since the experiment occurred in a closed en-
vironment, there was minimal contamination compared to 
conventional methods and the sensitivity is higher due to 
one more step in amplification.31,32 
We detected both HPV and HPV 16 positivity by real-
time PCR. In order to detect types other than 16, sequenc-
ing can be performed.
In conclusion, we aimed to detect the prevalence of HPV, 
especially type 16 in colposcopy patients as a specific group 
with cervical complaints and this is the first study reflecting 
the HPV results of colposcopy patients in our country. Since 
cervical cancer is an important public health problem among 
women and HPV, especially type 16 is significantly related 
with cervical cancer, detection of HPV will be helpful for 
designing effective cervical cancer prevention programs. We 
think that further studies including large numbers of colpos-
copy patients must be performed to evaluate the prevalance 
of HPV in this patient group.
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